CYTODYN INC.

August 30, 2022

VIA EDGAR

Office of Life Sciences

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, NE

Washington, DC 20549

Attention: Alan Campbell

 

Re:	CytoDyn Inc.

Registration Statement on Form S-3

File No. 333-267030

Request for Acceleration

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, CytoDyn Inc. (the “Company”) hereby respectfully requests acceleration of the effectiveness of the Company’s Registration Statement on Form S-3 filed on August 23, 2022 (File No. 333-267030) (the “Registration Statement”) so that the Registration Statement shall become effective at 9 am Eastern Time on September 2, 2022, or as soon as possible thereafter.

We would appreciate notification by telephone of the effective date of the Registration Statement and confirmation of such effectiveness in writing.

If you have any questions about the foregoing request, please contact our counsel, Mary Ann Frantz of Miller Nash LLP at (503) 880-0278, or the undersigned at (360) 980-8524. Thank you.

 

cc: Mary Ann Frantz, Miller Nash LLP